What Is Drawing Fresh Attention To Medtronic (MDT)?

Medtronic (MDT) just secured FDA clearance for its LigaSure RAS Maryland jaw device on the Hugo robotic-assisted surgery system. This technical update gives investors fresh detail on the group’s expanding surgical robotics tool kit.

Medtronic’s recent news flow has come alongside a clear shift in how the market is pricing the story, with the share price delivering a 16.9% 90 day share price return even though the year-to-date share price return is still down 3.4%, and the 5 year total shareholder return is also negative.

Scan Medtronic’s peers riding similar themes in surgical robotics and medical technology by reviewing the hand picked 95 robotics and automation stocks now shaping this corner of healthcare.

Medtronic is clearly building a broader surgical robotics platform, and the recent 90 day share price jump shows investors have noticed. The harder call is whether that renewed optimism already prices the business fairly today.

Most Popular Narrative: 2.7% Overvalued

Medtronic last closed at $92.77, while the most followed narrative pegs fair value at $90.37, so the gap is small but tilts to a slight premium. That framing puts more weight on the quality and durability of Medtronic’s cash flows than on chasing short term share price swings.

Diversification in my portfolio meant investing in the healthcare sector. I already owned Pfizer. Functional and technical analysis showed Medtronic plc to be a good addition for the longer term. Actual indicators for this moment: P/E fwd ~13.5, PEG ~1.6, Debt/Equity ~57%, EPS ~11%, Payout ~76%, and Operational Cash Flow approx. $7.3 billion. MACD above signal line, RSI 54.26, MOM and OBV positive. Medtronic plc recently acquired Scientia Vascular to expand its neurovascular technology portfolio. Although analysts are showing some caution and issuing various price targets, I found the timing of entry favorable. My investment horizon is 5 to 10 years. Medtronic plc is not spectacular in its growth but does grow over the long term. Medtronic plc is a dividend aristocrat. The number of years of dividend growth is 50 years. I cautiously bought a small group of 5 shares to monitor it more closely and potentially invest further. The healthcare weighting in my portfolio is now 2%.

See why 3 investors see Medtronic as 3% overvalued.

Result: Fair Value of $90.37 (OVERVALUED)

Still, Medtronic faces real pressure if surgical robotics uptake slows or if future device approvals and acquisitions fail to deliver the expected clinical traction.

Find out about the key risks to this Medtronic narrative.

Another View On Medtronic’s Valuation

Medtronic looks slightly overvalued against the $90.37 fair value in the leading narrative, yet our DCF model points the other way. At $92.77, the stock screens as trading below an estimated future cash flow value of $105.88, which implies investors might be underpaying for those projected cash streams.

The gap between a small premium to $90.37 and a discount to $105.88 leaves a wide valuation band. The key consideration is which set of assumptions about Medtronic’s future cash generation appears more realistic.

Look into how the SWS DCF model arrives at its fair value.

Next Steps

Feeling uncertain after weighing Medtronic’s mixed signals and valuation range is reasonable. Consider moving quickly to review the underlying data and stress test your own thesis using the 5 key rewards.

Looking for more investment ideas beyond Medtronic?

Medtronic can anchor a portfolio, but you give up a lot of potential if you stop your research here. Make time to scan other opportunities now.

• Target reliable cash generators that pair healthy cash flows with disciplined balance sheets by reviewing a focused list of solid balance sheet and fundamentals (23 results) built to spotlight financial resilience.
• Hunt for mispriced opportunities where quality and valuation intersect by working through a curated 29 high quality undervalued stocks that keeps fundamentals front and center.
• Prioritize resilience over drama and concentrate on steadier performers with a purpose built 30 resilient stocks with low risk scores designed to filter for lower risk profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com